Karishma Sukhdeo
Medical · Brooklyn, NYNPI 1073826251
Payments from drug & device makers
Across 173 payments — averaging $21.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$1K
- Novo Nordisk$268
- Amgen$209
- Lilly USA, LLC$202
- Amneal Pharmaceuticals LLC$187
- Corcept Therapeutics$167
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,747100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 49 | $1,037 |
| Novo Nordisk | 14 | $268 |
| Amgen | 10 | $209 |
| Lilly USA, LLC | 7 | $202 |
| Amneal Pharmaceuticals LLC | 9 | $187 |
| Corcept Therapeutics | 7 | $167 |
| Xeris Pharmaceuticals, Inc. | 7 | $143 |
| Chiesi USA, Inc. | 4 | $119 |
| Dexcom, Inc. | 5 | $117 |
| Phathom Pharmaceuticals, Inc. | 8 | $114 |
| Sanofi-aventis U.S. LLC | 7 | $103 |
| Madrigal Pharmaceuticals | 3 | $93 |
| Cequr Corporation | 2 | $88 |
| GRT US Holding, Inc. | 3 | $87 |
| Boehringer Ingelheim | 3 | $84 |
| Amryt Pharma Holdings Ltd | 3 | $84 |
| AstraZeneca | 4 | $82 |
| Medtronic | 3 | $70 |
| Johnson & Johnson | 2 | $64 |
| Insulet Corporation | 3 | $62 |
| AbbVie | 3 | $60 |
| Antares Pharma, Inc. | 3 | $55 |
| Astellas Pharma US Inc | 2 | $43 |
| Ultragenyx Pharmaceutical Inc. | 2 | $39 |
| Vistapharm, Inc. | 2 | $31 |
| Nevro Corp. | 1 | $30 |
| IBSA Pharma Inc. | 1 | $24 |
| Rhythm Pharmaceuticals, Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Intuity Medical Inc | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $12 |
| BETA Bionics, Inc. | 1 | $9 |
How this compares
$3,747 in reported general payments places this provider in the 85th percentile of 2,395 medical providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 95 | $158,014 |
| OzempicSemaglutide | 75 | $138,901 |
| JardianceEmpagliflozin | 101 | $127,703 |
| TrulicityDulaglutide | 35 | $63,751 |
| Tresiba Flextouch U-200Insulin Degludec | 54 | $50,595 |
| KerendiaFinerenone | 39 | $50,454 |
| SynjardyEmpagliflozin/Metformin Hcl | 42 | $48,857 |
| Repatha SureclickEvolocumab | 33 | $38,616 |
| Xigduo XrDapaglifloz Propaned/Metformin | 27 | $35,090 |
| JanumetSitagliptin Phos/Metformin Hcl | 30 | $29,677 |
| Gvoke Hypopen 2-PackGlucagon | 28 | $26,736 |
| ProliaDenosumab | 15 | $24,691 |
| RybelsusSemaglutide | 13 | $22,308 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $20,273 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 23 | $17,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $202 | $221,765130 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr | $84 | $193,930166 claims |
| Novo NordiskOzempic, Rybelsus | $268 | $161,21088 claims |
| BayerKerendia | $1,037 | $50,45439 claims |
| MerckJanumet | $17 | $29,67730 claims |
| AmgenProlia | $209 | $24,69115 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $103 | $20,27312 claims |
| AstraZenecaFarxiga | $82 | $13,49614 claims |
| AbbVieSynthroid | $60 | $3,92045 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $187 | $1,21495 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,395 medical providers in New York.
Other medical in Brooklyn
- Carl ClarkeBrooklyn$116K
- Catherine SekanskyBrooklyn$28K
- Phillip ScottiBrooklyn$22K
- Anna GorelikBrooklyn$15K
- Vita OklanderBrooklyn$13K
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Maureen ThyneNew York$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.